Video

DAP Guidelines and Whether Change is Needed

Author(s):

The use of dual anti platelet therapy is popular among cardio patients but questions remain of how long that therapy should continue after a cardiac event.

The use of dual anti platelet therapy is popular among cardio patients but questions remain of how long that therapy should continue after a cardiac event.

Robert Yeh, MD, MPH, from Massachusetts General Hospital discussed the results of a study on the topic at the American College of Cardiology Annual Scientific Sessions and Expo in San Diego.

Related Videos
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
Eric Lawitz, MD | Credit: UT Health San Antonio
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
A. Sidney Barritt, MD | Credit: UNC School of Medicine
© 2024 MJH Life Sciences

All rights reserved.